A New Era in Oncology

Harnessing the Power of Phosphoramidate Chemistry

Unlocking the Potential of Immunotherapy

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines.

NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.

Mission Statement

“To significantly improve the survival outcomes for patients and pioneer a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Discover more

Hugh Griffith CEO

Latest News

May 2025

NuCana Prices $7 Million Registered Direct Offering

March 2025

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

November 2024

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

More news

Contact NuCana

Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK

info@nucana.com

+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466

info@nucana.com

+1 617 663 5708

* These fields are required.